The Valeant Pipeline

Valeant's development pipeline strategy comprises new compounds as well as product life cycle management. The company's pipeline combines promising early and late-stage drug candidates that have unique formulations and mechanisms of action that address the need for new treatment regimens. In addition, our efforts in ophthalmology are focused on therapeutic areas including glaucoma, dry eye and post-operative inflammation, as well as a range of new contact lenses. Valeant also plans to strategically expand its pipeline by adding new compounds and product extensions through company and product acquisitions.